New data from the APeX-2 and APeX-S clinical trials show that HAE patients taking oral, once-daily berotralstat experienced sustained decreases in their attack frequency and improvements in quality of life (QoL) scores over 48 weeks. Berotralstat was also safe and generally well-tolerated over 48 weeks in both APeX-2 and APeX-S. The data were presented by … Continue reading Robust and Durable Reductions in HAE Attacks with Berotralstat